BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 21673678)

  • 1. The minimal incubation period from the onset of Barrett's oesophagus to symptomatic adenocarcinoma.
    den Hoed CM; van Blankenstein M; Dees J; Kuipers EJ
    Br J Cancer; 2011 Jul; 105(2):200-5. PubMed ID: 21673678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surveillance in patients with long-segment Barrett's oesophagus: a cost-effectiveness analysis.
    Kastelein F; van Olphen S; Steyerberg EW; Sikkema M; Spaander MC; Looman CW; Kuipers EJ; Siersema PD; Bruno MJ; de Bekker-Grob EW;
    Gut; 2015 Jun; 64(6):864-71. PubMed ID: 25037191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of oesophageal adenocarcinoma in individuals with Barrett's oesophagus.
    Holmberg D; Ness-Jensen E; Mattsson F; El-Serag HB; Lagergren J
    Eur J Cancer; 2017 Apr; 75():41-46. PubMed ID: 28214656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NSAIDs, statins, low-dose aspirin and PPIs, and the risk of oesophageal adenocarcinoma among patients with Barrett's oesophagus: a population-based case-control study.
    Masclee GM; Coloma PM; Spaander MC; Kuipers EJ; Sturkenboom MC
    BMJ Open; 2015 Jan; 5(1):e006640. PubMed ID: 25633286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Barrett's oesophagus patients with low-grade dysplasia can be accurately risk-stratified after histological review by an expert pathology panel.
    Duits LC; Phoa KN; Curvers WL; Ten Kate FJ; Meijer GA; Seldenrijk CA; Offerhaus GJ; Visser M; Meijer SL; Krishnadath KK; Tijssen JG; Mallant-Hent RC; Bergman JJ
    Gut; 2015 May; 64(5):700-6. PubMed ID: 25034523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett's oesophagus: a systematic review and meta-analysis.
    Singh S; Garg SK; Singh PP; Iyer PG; El-Serag HB
    Gut; 2014 Aug; 63(8):1229-37. PubMed ID: 24221456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oesophageal cancer incidence and mortality in patients with long-segment Barrett's oesophagus after a mean follow-up of 12.7 years.
    Hage M; Siersema PD; van Dekken H; Steyerberg EW; Dees J; Kuipers EJ
    Scand J Gastroenterol; 2004 Dec; 39(12):1175-9. PubMed ID: 15742992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of surveillance for Barrett's oesophagus on tumour stage and survival of patients with neoplastic progression.
    Kastelein F; van Olphen SH; Steyerberg EW; Spaander MC; Bruno MJ;
    Gut; 2016 Apr; 65(4):548-54. PubMed ID: 25903690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The incidence of Barrett's oesophagus and oesophageal adenocarcinoma in the United Kingdom and The Netherlands is levelling off.
    Masclee GM; Coloma PM; de Wilde M; Kuipers EJ; Sturkenboom MC
    Aliment Pharmacol Ther; 2014 Jun; 39(11):1321-30. PubMed ID: 24738722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and Validation of a Model to Determine Risk of Progression of Barrett's Esophagus to Neoplasia.
    Parasa S; Vennalaganti S; Gaddam S; Vennalaganti P; Young P; Gupta N; Thota P; Cash B; Mathur S; Sampliner R; Moawad F; Lieberman D; Bansal A; Kennedy KF; Vargo J; Falk G; Spaander M; Bruno M; Sharma P
    Gastroenterology; 2018 Apr; 154(5):1282-1289.e2. PubMed ID: 29273452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 'Missed' oesophageal adenocarcinoma and high-grade dysplasia in Barrett's oesophagus patients: A large population-based study.
    van Putten M; Johnston BT; Murray LJ; Gavin AT; McManus DT; Bhat S; Turkington RC; Coleman HG
    United European Gastroenterol J; 2018 May; 6(4):519-528. PubMed ID: 29881607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnosis and risk stratification of Barrett's dysplasia by flow cytometric DNA analysis of paraffin-embedded tissue.
    Choi WT; Tsai JH; Rabinovitch PS; Small T; Huang D; Mattis AN; Kakar S
    Gut; 2018 Jul; 67(7):1229-1238. PubMed ID: 28642331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aberrant p53 protein expression is associated with an increased risk of neoplastic progression in patients with Barrett's oesophagus.
    Kastelein F; Biermann K; Steyerberg EW; Verheij J; Kalisvaart M; Looijenga LH; Stoop HA; Walter L; Kuipers EJ; Spaander MC; Bruno MJ;
    Gut; 2013 Dec; 62(12):1676-83. PubMed ID: 23256952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett's multifocal high-grade dysplasia or adenocarcinoma.
    Weston AP; Badr AS; Hassanein RS
    Am J Gastroenterol; 1999 Dec; 94(12):3413-9. PubMed ID: 10606296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The evolution and outcome of surveillance of Barrett's oesophagus over four decades in a UK District General Hospital.
    Royston C; Caygill C; Charlett A; Bardhan KD
    Eur J Gastroenterol Hepatol; 2016 Dec; 28(12):1365-1373. PubMed ID: 27571366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MIC-1/GDF15 in Barrett's oesophagus and oesophageal adenocarcinoma.
    Fisher OM; Levert-Mignon AJ; Lord SJ; Lee-Ng KK; Botelho NK; Falkenback D; Thomas ML; Bobryshev YV; Whiteman DC; Brown DA; Breit SN; Lord RV
    Br J Cancer; 2015 Apr; 112(8):1384-91. PubMed ID: 25867265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of malignant progression in patients with Barrett's oesophagus: a Dutch nationwide cohort study.
    de Jonge PJ; van Blankenstein M; Looman CW; Casparie MK; Meijer GA; Kuipers EJ
    Gut; 2010 Aug; 59(8):1030-6. PubMed ID: 20639249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of p53 immunohistochemistry in conjunction with routine histology improves risk stratification of patients with Barrett's oesophagus during routine clinical care.
    Tokuyama M; Geisler D; Deitrick C; Fasanella KE; Chennat JS; McGrath KM; Pai RK; Davison JM
    Histopathology; 2020 Sep; 77(3):481-491. PubMed ID: 32431062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adam, Eve and the reflux enigma: age and sex differences across the gastro-oesophageal reflux spectrum.
    Royston C; Bardhan KD
    Eur J Gastroenterol Hepatol; 2017 Jun; 29(6):634-639. PubMed ID: 28151751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surveillance and follow-up strategies in patients with high-grade dysplasia in Barrett's esophagus: a Dutch population-based study.
    Verbeek RE; van Oijen MG; ten Kate FJ; Vleggaar FP; Schipper ME; Casparie MK; van Baal JW; Siersema PD
    Am J Gastroenterol; 2012 Apr; 107(4):534-42. PubMed ID: 22270082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.